Why the study?
Does clopidogrel improve cardiovascular outcomes compared with aspirin in patients with symptomatic atherosclerosis?
Population
Patients with symptomatic atherosclerosis and those at very high risk of further atherothrombotic events
Comparison
Clopidogrel (ADP receptor antagonist) vs Aspirin
Design
Review
Authors
Loading...
May favor clopidogrel in symptomatic atherosclerosis for efficacy and tolerance; leaves open confirmation in contemporary RCTs.
Does clopidogrel improve cardiovascular outcomes compared with aspirin in patients with symptomatic atherosclerosis?
This review highlights the clinical benefits of clopidogrel over aspirin in high-risk atherothrombotic patients, including better efficacy, improved GI tolerance, and potential advantages in patients taking ACE inhibitors.
Julien Bogousslavsky (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: